Phosphate binders are routinely prescribed to lower serum phosphorus in patients with CKD. But do they actually reduce total body phosphorus — or just shift where phosphorus is excreted? A fascinating metabolic balance study in peritoneal dialysis patients helps us unpack this question.
The reference for today’s post is:
I first heard this study discussed at the Canadian Association of Nephrology Dietitians conference, and it absolutely piqued my interest. So I tracked down the full paper and gave it a careful read.
Here’s what it showed.
Why Serum Phosphorus May Not Tell the Whole Story
Hyperphosphatemia is common in CKD, particularly in patients receiving dialysis. Most guidelines recommend lowering serum phosphorus toward the normal laboratory range. In practice, this often means:
- Dietary phosphorus restriction
- Phosphate binders
- Or both
We know from multiple studies that phosphate binders lower serum phosphorus.
What we don’t know nearly as well is whether lowering serum phosphorus actually reduces total body phosphorus.
And this matters.
Only a very small fraction of the body’s total phosphorus is circulating in the blood. Most phosphorus is stored in bone and soft tissues. Emerging evidence suggests that the complications we worry about — vascular calcification, soft tissue calcification, cardiovascular disease — may be driven more by positive phosphorus balance than by serum levels alone.
So the real question becomes:
Does lowering serum phosphorus correct excess phosphorus balance?
Do Phosphate Binders Increase Fecal Phosphorus Excretion?
If you’re like me, you’ve probably told patients that phosphate binders “stick to phosphorus in the gut so you can poop it out.”
But how often do we actually confirm that this happens?
Interestingly, very little data exist on fecal phosphorus excretion in patients taking binders. The authors of this study highlighted this gap — and specifically measured it.
Study Design: A 47-Day Metabolic Balance Study in Peritoneal Dialysis
This was an intensive metabolic balance study conducted in:
7 maintenance peritoneal dialysis (PD) patients
Inclusion Criteria
Participants were:
- 30–65 years old
- On PD for >4 months
- Within a reasonable iPTH range
- Free from acute illness or infection
- Adherent to medical therapy
A Remarkably Controlled Setting
Participants stayed in a clinical trials unit for 47–49 days (yes — nearly seven weeks!).
Before starting, they stopped their phosphate binders for 2–3 weeks.
While in the unit:
- All food was provided
- Diet was standardized
- PD treatments continued as usual
This level of dietary control is rare — and powerful — in phosphorus research.
What Phosphate Binder and Doses Were Used?
The binder studied was lanthanum carbonate.
Each participant received:
- 500 mg three times daily
- 1,000 mg three times daily
- 1,500 mg three times daily
Each dose was given for 12 days in randomized order.
Importantly, dietary phosphorus intake remained constant across all phases.
Average phosphorus intake was:
980 ± 236 mg/day
How Was Total Body Phosphorus Balance Measured?
After allowing 5–7 days to reach a new balance state at each dose, researchers collected:
- Rejected food
- Emesis
- Urine
- Dialysate outflow
- Feces
All samples were analyzed for phosphorus and lanthanum content. Serum phosphorus was also measured.
This allowed the researchers to calculate:
Total phosphorus intake vs total phosphorus output
→ In other words: phosphorus balance.
What Happened to Serum Phosphorus?
As expected:
Higher doses of lanthanum were associated with:
- Lower serum phosphorus levels
- Higher fecal phosphorus excretion
So far, so good.
Did Lanthanum Reduce Total Body Phosphorus Balance?
Here’s where things get interesting.
Although fecal phosphorus excretion increased with higher lanthanum doses, urinary and dialysate phosphorus excretion decreased.
The net result?
Total phosphorus balance remained unchanged.
In other words:
Lanthanum shifted how phosphorus left the body — but did not change the overall balance.
What Does This Mean?
This study suggests that traditional phosphate binders may lower serum phosphorus without improving total body phosphorus balance.
That is a provocative finding.
Now, important context:
- This study was small (n=7).
- It was short-term.
- It included only PD patients.
We cannot conclude that phosphate binders have no long-term benefit.
But it does raise important questions:
- Is serum phosphorus an adequate marker of phosphorus burden?
- Could homeostatic adaptation offset fecal phosphorus increases?
- Is phosphorus balance a better predictor of outcomes than serum levels?
This may also help explain why many observational studies have struggled to demonstrate that lower serum phosphorus consistently improves survival.
Clinical Implications for Renal Dietitians
This study doesn’t mean we should stop using phosphate binders.
But it does suggest that:
- Lower serum phosphorus does not automatically equal lower total phosphorus burden.
- Phosphorus balance may be more complex than we assume.
- We need more outcome-driven trials examining cardiovascular events and mortality.
As clinicians, it reminds us to think critically about surrogate markers.
Key Takeaways
- Lanthanum carbonate lowered serum phosphorus in PD patients.
- It increased fecal phosphorus excretion.
- However, total body phosphorus balance did not change.
- Serum phosphorus may not fully reflect phosphorus burden.
- More research is needed to determine whether phosphate binders improve meaningful clinical outcomes.
